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Abstract
Background: Prostate cancer is the most common male cancer in the Western world but is highly
heterogeneous in disease progression and outcomes. Consequently, the most substantial morbidity
may actually arise from the adverse psychosocial impact of distress in decision-making and long
term quality of life effects such as impotence. This paper presents the design of a randomised
controlled trial of a decision support/psychosocial intervention for men newly diagnosed with
localised prostate cancer.
Methods/Design: 350 men per condition (700 men in total) have been recruited after diagnosis
and before treatment through urology private practices and hospital outpatient clinics and
randomised to 1) a tele-based nurse delivered five session decision support/psychosocial
intervention or 2) a usual care control group. Two intervention sessions are delivered before
treatment that address decision support, stress management and preparation for treatment. Three
further sessions are provided three weeks, seven weeks and five months after treatment that focus
on adjustment to cancer, problem solving and coping with treatment side effects. Participants are
assessed at baseline (before treatment) and 2, 6, 12, 24 and 36 months post-treatment. Outcome
measures include: cancer threat appraisal; decision-related distress and bother from treatment side
effects; involvement in decision making; satisfaction with health care; heath care utilisation; use of
health care resources; and a return to previous activities.
Discussion: The study will provide recommendations about the efficacy of early decision support
to facilitate adjustment after prostate cancer. As well the study will identify men diagnosed with
localised prostate cancer at risk of poorer long term psychosocial adjustment.
Trial Registration: ACTRN012607000233426.
Published: 24 July 2008
BMC Cancer 2008, 8:207 doi:10.1186/1471-2407-8-207
Received: 2 July 2008
Accepted: 24 July 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/207
© 2008 Chambers et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2008, 8:207 http://www.biomedcentral.com/1471-2407/8/207
Page 2 of 7
(page number not for citation purposes)
Background
Internationally, prostate cancer is the second most com-
mon cancer diagnosed in men and the sixth most com-
mon cause of death [1]. With increasing rates of diagnosis
and improved survival from prostate cancer the public
health impact of prostate cancer is high. However, prob-
lematically, the benefits of early diagnosis and treatment
of prostate cancer remain contentious. Prostate cancer is a
heterogeneous disease and the risk of mortality from
localised disease is difficult to quantify owing to the can-
cer's relatively slow growth rate. For example, 30–40% of
all men aged over 50 years will be estimated to have his-
tological evidence of prostate cancer, but of these only one
in four men will develop clinically evident disease and
only 1 in 14 will have disease that will prove lethal [2].
This means that many prostate cancers are not life threat-
ening and treatment for men in this category may provide
no potential benefit. On this basis, after the diagnosis of
localised prostate cancer it is recommended that all men
be advised of three possible treatment options at a mini-
mum: close observation (no active treatment initially with
intervention based on disease progression) or clinical
monitoring; radiation therapy; or radical prostatectomy
[3].
If watchful waiting reserves medical treatment for symp-
toms of prostate cancer, then although quality of life may
be preserved, the opportunity for cure may be missed. For
this reason, the more active surveillance strategy of close
surveillance has evolved since a significant proportion of
patients with low-risk prostate cancer do not progress in
the short to intermediate term and that most of those who
do progress are still able to have definitive therapeutic
interventions without losing the likelihood of cure. By
contrast, potentially curative treatments for localized
prostate cancer such as surgery or radiation therapy have
a range of deleterious side effects including impotence,
urinary incontinence, bowel injury, urethral stricture and
rarely death [4]. In addition, for the more aggressive forms
of prostate cancer, there is a not-insignificant risk that, in
spite of undergoing definitive treatment with curative
intent with its associated morbidities, metastatic disease
may be detected subsequently so that this unfortunate
subset of patients experience locally-invasive treatments
with seemingly little or no benefit. Therefore, men with
localized prostate cancer are faced with a difficult treat-
ment decision and decision-related distress is a highly
salient aspect of their illness experience.
Most men prefer active involvement in their prostate can-
cer treatment decisions [5], however many find this diffi-
cult. First, as with most cancer treatments it is uncertain
whether a cure will be attained. However, as outlined pre-
viously, for localised prostate cancer it is currently conten-
tious whether any survival gain is likely. Second, side
effects from treatment for localised prostate cancer are sig-
nificant and so threat to the man's survival is balanced by
threat to quality of life from changes to sexual, urinary
and bowel functioning. Third, the risk probabilities for
complications from treatment of localised prostate cancer
are ambiguous with relevant local published outcome
data often unavailable. For example, based mainly on
North American data, risk estimates for impotence vary
from 14% to 91% [4]. In uncertain and ambiguous situa-
tions, people find it difficult to choose [6]. Consequently,
decision related distress is common for men after diagno-
sis with 63% of men reporting high decision-related dis-
tress that persists one year after treatment for 42% of all
men [7]. As well, decision regret has been found to be
associated with poorer quality of life three years after
treatment for localised prostate cancer, with under-
informed men at greater risk of regret [8].
Adding to this, the experience of the diagnosis and treat-
ment of cancer is in itself a traumatic life event. The diag-
nosis of cancer poses a threat to the individual's survival
and future hopes, to their physical and psychological
sense of self, and to their social functioning. Elevated psy-
chological distress such as anxiety and depression is com-
mon at initial diagnosis and during active treatments that
are often accompanied by unpleasant side effects [9].
Patients' concerns may include fear and stigma associated
with the diagnosis; fears about cancer recurrence; con-
cerns about the physical effects of both the cancer and
treatments; disturbances in self image, intimacy and sexu-
ality; and disruption to daily activities [10].
Although many men report low psychological distress
after diagnosis and treatment for prostate cancer, a sub-
stantial minority, between 14% and 38% of men, are
highly distressed [7,11-14]. In addition, one third report
moderate to high unmet supportive care needs in the
domains of sexuality, psychological distress and treat-
ment information up to five years after treatment [10].
Problematically, by contrast to women, men are less likely
to seek help for psychological distress and are under-rep-
resented as clients to cancer support services. Thus, acces-
sible support services for men with prostate cancer that are
targeted to their specific concerns are critical. As well, psy-
chosocial interventions that are targeted to those men at
highest risk of distress are likely to be most efficacious [9].
A number of randomised controlled trials have been
undertaken to assess the effectiveness of psychosocial
interventions for men with localised prostate cancer.
Interventions have included a range of therapeutic
approaches such as psycho-education and peer discussion
[15], uncertainty management [16], symptom manage-
ment [17]; cognitive behaviour and stress management
[18]. These studies have variously shown positive effectsBMC Cancer 2008, 8:207 http://www.biomedcentral.com/1471-2407/8/207
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such as more stable employment, less sexual bother,
improved general QOL and perceived stress management
skills, improved uncertainty management, cognitive
reframing and problem solving, and continence manage-
ment and less cancer worry. However, none of these stud-
ies have targeted men at diagnosis when distress is
highest, or addressed decision-related distress, or fol-
lowed men past twelve months post-intervention. One
randomised control trial has been reported for a self-effi-
cacy information intervention delivered to men at diagno-
sis [19]. Men in the intervention group reported less
anxiety and greater involvement in decision making, how-
ever the study involved a small convenience sample of 60
men with only a short six week follow up. Given the long
lasting nature of treatment side effects such as erectile dys-
function and the potential for late decision-related dis-
tress and regret with implications beyond the patients
themselves, longer term follow up of 2 and 3 years when
treatment side effects have stabilised is essential.
In addition, there is considerable heterogeneity in the lon-
gitudinal course of adjustment of cancer patients as a
whole and in regard to the different diagnostic groups to
which they belong. Although the group means of func-
tioning-related variables tend to shift in the more positive
direction over time, many individual patients do not dem-
onstrate such a pattern. Specifically, subgroups of patients
may improve over time, by returning to baseline function-
ing, or may improve but not return to baseline function-
ing, or indeed may become worse over time [20]. After
prostate cancer the trajectory of adjustment appears to dif-
fer for different subgroups of men: optimism and cancer
threat appraisal are important in determining decision-
related and psychological distress and global quality of
life. In a prospective study in which 111 men were fol-
lowed from diagnosis to one year post-treatment, opti-
mism was a significant prospective and concurrent
predictor of decision-related distress, with the effect medi-
ated by proximal cancer threat appraisal [21]. Decision-
related distress and optimism at diagnosis together pre-
dicted 45% of the variance of decision-related distress two
months after treatment; decision-related distress at diag-
nosis and concurrent threat appraisal predicted 47% of
this distress twelve months after treatment. Further two
year follow up data found that, after adjusting for physical
symptoms, optimism at diagnosis was a significant pre-
dictor of the level of psychosocial adjustment at each
occasion of measurement but was not a predictor of the
slope of psychosocial adjustment over time (unpublished
data). Cancer threat appraisal was a partial and a full
mediator of the effect of optimism on negative adjust-
ment and positive adjustment, respectively. In turn, can-
cer threat appraisal predicted both the initial intercept and
the slope of the trajectory of adjustment over time. Men
whose cancer threat appraisal became more positive over
time had a decreasing trajectory of negative adjustment.
As men's cancer threat appraisal became more negative,
their adjustment trajectory worsened. Previous
approaches to decision support have been primarily util-
ity based and have not considered the central role of cog-
nitive appraisal in decision distress. We propose that
including strategies that target negative cancer threat
appraisals into a multi-component intervention that pro-
vides decision counselling as well as addressing the psy-
chological and physical challenges associated with
localised prostate cancer will be more effective.
Methods/Design
Study aims and hypotheses
The study aims first to assess the effectiveness of a decision
support/psychosocial intervention in supporting men's
decision making and improving their adjustment up to
three years post-treatment when compared to usual care.
Second, we will identify subgroups of men diagnosed
with localised prostate cancer at risk of poorer long term
psychosocial adjustment.
We hypothesise that up to three years after treatment for
localised prostate cancer:
1. By contrast to men in usual care, men who receive the
intervention will have a more positive cancer threat
appraisal; less decision-related distress and bother from
treatment side effects; more active involvement in deci-
sion making; greater satisfaction with health care; lower
heath care utilisation; and a quicker and sustained return
to previous activities.
2. Men with higher baseline decision-related and psycho-
logical distress will experience greater benefits from the
intervention compared to men with lower baseline dis-
tress.
3. More optimistic men with more positive cancer threat
appraisals will have an improved trajectory of adjustment
by comparison to pessimistic men with a more negative
appraisal.
Intervention
Decision support is underpinned by the definition of an
optimal decision as one that is both informed and in
agreement with the person's values [22]. Existing evi-
dence-based patient education materials and booklets are
integrated into the intervention [23,24]. Working with
these materials a nurse counsellor assists the patient to
select out the information most relevant to his situation,
his values and concerns, and also checks his comprehen-
sion of content in an ongoing educative process. Decision
support is paired with the challenging of unhelpful cogni-
tions; psycho-education about adjustment to prostateBMC Cancer 2008, 8:207 http://www.biomedcentral.com/1471-2407/8/207
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cancer; stress reduction techniques; and education and
coaching about problem solving skills relevant to the side
effects associated with prostate cancer treatments [25].
ProsCan for Men [26] is telephone delivered over five ses-
sions by nurse counsellors guided by structured coun-
seling protocols and supervised by a clinical psychologist
with specialist training in oncology and clinical supervi-
sion. Supplementary self help worksheets that were devel-
oped specifically for this project are also utilised. Two
sessions are delivered pre-treatment that focus on decision
support, stress management and preparation for treat-
ment. Two further sessions are delivered three and seven
weeks after treatment focusing on adjustment to cancer,
problem solving and coping with treatment side effects,
with a fifth booster session five months after treatment
focussing on treatment side effects and preparing for the
future.
Participants
Approximately 700 men newly diagnosed with prostate
cancer (350 men in each condition) have been recruited
into the ProsCan for Men study through committed par-
ticipation by a large proportion of Queensland urologists.
To recruit a broader and more diverse patient group the
study was sited in the three cities of Brisbane, Townsville
and Mackay that includes the geographic catchment areas
of both Brisbane and environs and North Queensland.
Men were referred to the project by their urologists if they
were judged at the time of diagnosis to have localised
prostate cancer suitable for treatment with curative intent
and have no evidence of metastatic disease on scans and
x-rays. Inclusion criteria were that the men must: (1) have
been newly diagnosed with localised prostate cancer (2)
be able to read and speak English (3) have no previous
history of head injury, dementia or psychiatric illness and
(4) have no other concurrent cancer. Informed written
consent was obtained by study trained research nurses
who contacted potential participants after referral to the
project.
Study integrity
Ethical approval has been obtained from the Queensland
University of Technology Human Research Ethics Com-
mittee as well as the ethics committees of nine public hos-
pitals in Queensland. The study design is guided by the
CONSORT statement [27]. Randomisation to study con-
dition was conducted following the completion of base-
line assessment. Assessments are completed through
telephone interviews and self-report pen and paper meas-
ures and project staff tracking assessments are blinded to
condition. Randomisation occurred in blocks of 12, with
each condition randomly generated 6 times within each
block to ensure an unpredictable allocation sequence with
equal numbers of couples in each group at the completion
of each block. This sequence was undertaken by the
project manager and concealed from investigators. Ther-
apy is manualised with 25% of intervention calls recorded
and reviewed to ensure treatment adherence. All analyses
will be conducted on the basis of intention to treat.
Materials
A series of previously validated and reliable self report
measures are administered by mail to men in both the
control and intervention groups at baseline, 2, 6, 12, 24
and 36 months after treatment. Brief single item screening
measures for decision-related and psychological distress
are used and will be cross validated to decisional conflict
and psychological distress measures. Optimism is
included as a predictor of adjustment and cancer threat
appraisal as a moderator of intervention effect. Outcome
variables are psychological distress; overall and domain
specific QOL; decisional conflict; decision regret; involve-
ment in decision making; satisfaction with and utilisation
of health care. Disease variables (e.g. cancer grade, stage)
are assessed though medical and cancer registry records
review. Use of medical services and associated costs will
be assessed through Medicare Australia records.
Self report measures
Distress screening
The single item Distress Thermometer is widely used as a
screening measure to assess global psychological distress
[28]. This scale asks men how distressed they feel on a ten
point scale. This scale has good sensitivity and specificity
when used with a cut off point of > 5 [9]. As well, we have
developed in our pilot work a novel single item five point
scale to screen for high decision-related distress. This sin-
gle item decision distress scale correlates highly with total
Decisional Conflict Scale scores (r = .58, p < .005) [26]
and decision status (r = .44, p < .05). A cut off of >2.5 indi-
cates high decision distress associated with decision delay.
Optimism
Dispositional optimism is defined as generalised outcome
expectancies where optimistic people have positive
expectancies and pessimistic people have negative expect-
ancies and is assessed by the Life Orientation Test-Revised
(LOT-R [29]). Internal consistency for the LOT-R is very
good. Dispositional optimism is predictive of psycholog-
ical distress after a cancer diagnosis with more optimistic
patients experiencing less distress [21].
Cancer threat appraisal
Men's cancer threat appraisal is measured with the Con-
structed Meaning Scale (CMS [30]) that assesses a person's
cognitive construal over the week leading up to the time
of assessment of the perceived consequences of their can-
cer diagnosis for their: a) sense of identity; b) interper-
sonal relationships; c) and generalised future prospects.BMC Cancer 2008, 8:207 http://www.biomedcentral.com/1471-2407/8/207
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The measure has good internal consistency. Positive
appraisals of the meaning of the cancer diagnosis as
assessed by the CMS are predictive of lower decision-
related distress in men with prostate cancer [21].
Psychological distress
The Revised Impact of Events Scale (RIES [31,32]) is used
to measure men's psychological distress. The RIES has 15
items and contains two subscales: intrusion and avoid-
ance. Internal consistencies for the RIES subscales are
good. Epping-Jordan [33] suggest that intrusion and
avoidance are more sensitive measures of psychological
distress after a cancer diagnosis than generalised distress
measures. In men treated for localised prostate cancer
intrusion and avoidance have been found to be related to
poorer mental health outcomes [34].
Decision-related distress
For decision-related distress we assess both decisional
conflict and decision regret. The Decisional Conflict Scale-
Revised (DCS [21,35]) measures a person's perception of
the difficulty involved in making a decision about medi-
cal treatments. The revised scale has 19 items covering
decisional uncertainty, feeling uninformed, unclear about
personal values, and unsupported in decision making,
and perceptions of effective decision making. The DCS
has been validated in a range of population groups and is
sensitive to people making different health decisions, and
to the effect of decision aids, with good internal consist-
ency for the total scale. Health decisions assessed with this
scale include treatment for localised prostate cancer. The
Decision Regret Scale is a 5-item scale measuring distress
or remorse after a health decision [36]. The scale has good
internal consistency and has been validated in a range of
populations including men considering prostate cancer
treatment [36].
Desire for involvement in decision making
To assess desire for involvement in treatment decision
making men were asked how they would prefer decisions
about their prostate cancer treatment to be made on a five
point Likert type scale from the doctor alone to you alone
[37]. After treatment self report of actual involvement in
decision making is assessed on this scale.
Subjective well being – satisfaction with life
Subjective well being is an important cognitive-judge-
mental psychological outcome from a stressful event that
equates with global quality of life [38]. Subjective well
being is measured with the generic five item Satisfaction
with Life measure (SWL [39]). The internal consistency for
SWL is good.
Treatment side effects
Urinary, sexual and bowel problems associated with pros-
tate cancer treatments are measured by the symptom and
bother subscales of the UCLA Prostate Cancer Index [40].
This 20 item measure includes subscales for each of the
three problem domains of urinary, sexual and bowel func-
tioning. Men respond with the frequency with which they
experience symptoms and bother. Internal consistencies
for these subscales are acceptable.
Health related Quality of Life
Health related quality of life is assessed with the SF-36
that is the most widely used QOL measure in the world
with norms for the Australian general population availa-
ble. The SF-36 [41] contains a mental health and physical
health summary scale suitable to measure the impact of
the intervention on patients' wellbeing. The SF-36 will
also be used for translation into a health status measure
for economic evaluation – the SF-6D. The SF-6D generates
preference-based valuations of health states, allowing der-
ivation of quality-adjusted life years.
Utilisation of health care
Data on health service utilisation will include hospitaliza-
tions, surgical procedures, diagnostic and imaging serv-
ices, prescribed medications, GP and specialist visits, and
other health professional visits. These will be measured
using a combination of recommended valid and reliable
methods [42]. Medicare Australia will provide service and
cost data on GP services, drug use, diagnostic and imaging
tests. Queensland Health will provide service and cost
data on hospitalization and surgical procedures through
the Queensland Hospital Admitted Patient Data Collec-
tion (and includes private and public hospital data). Data
on emergency hospital visits and other outpatient visits
will be abstracted from patient medical charts and valued
using the Australian-Diagnostic Related Group cost esti-
mates. The above health utilisation data will be collected
by self-report questionnaires. Data collected by objective
data methods will be verified by these self-reports where
overlaps occur. Collectively, these data sources will give a
comprehensive account on the typical health services used
by our participants in the diagnosis and management of
prostate cancer (and for all their health needs) during the
study period and potential savings that may be attributa-
ble to the intervention.
Employment outcomes
Questions will be asked on pre-cancer and current
employment status, time off work, returning to work,
receipt of sickness and other benefits, unpaid work activi-
ties, changes in work role, consequences at work due to
cancer, perceived work productivity, assistance from fam-
ily or others, and carer's or partner's work patterns since
the participant's cancer diagnosis.BMC Cancer 2008, 8:207 http://www.biomedcentral.com/1471-2407/8/207
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Statistical analyses
The study is a multivariate, two condition randomised
controlled trial with repeated measures across time. The
analysis of longitudinal differences in outcome will use
two complementary statistical approaches: multilevel
modelling (MLM) and growth mixture modelling (GMM)
as applied to randomized preventative interventions by
Muthén [43]. These procedures allow the testing of typical
group level predictions such as Hypothesis 1 that men in
the intervention group will have better psychosocial out-
comes than the control group. However, they further per-
mit the true assessment of Hypotheses 2 and 3 that deal
with the impact of the intervention on heterogeneous
subgroups of men. GMM is a latent variable technique
that identifies subgroups of trajectories of change over
time within a sample and allows the assessment of predic-
tors of membership of trajectory groups, such as a high
baseline distress group in the present proposal who are
predicted to exhibit the strongest response of men in the
intervention condition. GMM has the advantages of
allowing use of all data points, which maximizes power to
detect effects and reduces bias owing to missing data in
longitudinal studies. Although power calculations are not
well articulated for GMM, simulation studies suggest that
the initial sample size of 350 per group will give at least
80% power to detect intervention effects of .5 (moderate)
even with completion rates of 70% that are lower than the
projected 85% [44]. As well, 350 per condition is suffi-
cient to allow for the likely 2–3 subgroups of low to high
risk men to be identified in the GMM.
Unlike previous approaches using ordinary least squares
regression, MLM and GMM allow both the starting points
and the rates of change in outcome variables for individ-
ual men to be parameters in the statistical models. The
particular usage of MLM and GMM in the present applica-
tion is for longitudinal effects where the number of assess-
ments in time is a crucial parameter. Importantly, by
adding two more assessment time points to the current
RCT, the proposed study will allow analysis of both curvi-
linear change and of heterogeneity in response to inter-
vention and the cancer experience. This will provide
major insight into the likely long term impact of the inter-
vention on men's health and well-being.
A cost-effectiveness analysis will determine if the interven-
tion represents a good health investment. This involves
the assessment of the efficacy data in conjunction with
cost data collected on intervention resources, patient
expenses, medical care utilization and producing incre-
mental ratios of cost per quality-adjusted life year. The
extended assessment time points will enhance the eco-
nomic analysis because patient outcomes will be more
comprehensive facilitating higher precision on the impact
of prostate cancer on resource use.
Discussion
This research will provide recommendations about the
efficacy of tele-based nurse counselling to: facilitate more
effective decision making about treatment; improve long
term adjustment after prostate cancer; as well elucidating
the potential economic value of the intervention. In addi-
tion, we will be able to validate approaches to identifying
patients at high risk of poorer long term adjustment out-
comes so that more in depth and intensive care can be
directed to those patients with higher need [9]. It has been
argued that future research into the effectiveness of psy-
chosocial interventions in cancer should: be theory based
and articulate the mechanisms of change; target patients
at the point of highest distress and greatest need; include
sexual adjustment as an outcome; use longitudinal
designs with longer term follow up; and identify the mod-
erators of treatment effect [45]. The current research
addresses these recommendations and is the first of its
kind internationally to do so for men with prostate cancer.
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